# A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

> **NCT05532163** · PHASE4 · TERMINATED · sponsor: **Biogen** · enrollment: 1 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT05532163
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-23
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-10-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532163, "A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05532163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*